Omnicell Inc (OMCL) Stock
Key stats
- Market cap
- $1.64B
- Price / Earnings ratio
- 41.3x
- EPS (TTM)
- $0.85
- Volume
- Loading
- 52-week high
- $55.00
- 52-week low
- $29.06
- Next earnings report
- 29 Oct 2026
Source: third-party data provider, as of October 17, 2026
Compare with OMCL
Recent news
Is This the Right Time to Retain Omnicell Stock in Your Portfolio?
Is This the Right Time to Retain Omnicell Stock in Your Portfolio?
OMCL
Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026
Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026
OMCL
Omnicell (OMCL) is a Top-Ranked Value Stock: Should You Buy?
Omnicell (OMCL) is a Top-Ranked Value Stock: Should You Buy?
OMCL
Here's Why Omnicell (OMCL) is a Strong Value Stock
Here's Why Omnicell (OMCL) is a Strong Value Stock
OMCLNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 57.17
- MACD 12/26/9
- 0.45
- EMA 9 of MACD
- 0.14
- MACD histogram
- 0.31
- SMA 50
- $34.63
- Price above SMA 50
- EMA 50
- $35.44
- Price above EMA 50
- SMA 200
- $39.69
- Price below SMA 200
- EMA 200
- $38.10
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.31 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Is This the Right Time to Retain Omnicell Stock in Your Portfolio?
Is This the Right Time to Retain Omnicell Stock in Your Portfolio?
OMCLOmnicell to Release Third Quarter 2026 Financial Results on October 29, 2026
Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026
OMCLOmnicell (OMCL) is a Top-Ranked Value Stock: Should You Buy?
Omnicell (OMCL) is a Top-Ranked Value Stock: Should You Buy?
OMCLHere's Why Omnicell (OMCL) is a Strong Value Stock
Here's Why Omnicell (OMCL) is a Strong Value Stock
OMCL
Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference
Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference
OMCL
Why Omnicell (OMCL) is a Top Value Stock for the Long-Term
Why Omnicell (OMCL) is a Top Value Stock for the Long-Term
OMCL
Omnicell President Sells 6,753 Shares
Omnicell President Sells 6,753 Shares
OMCL
Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins
Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins
OMCL
OMCL Falls 20.1% in a Month as Booking and Margin Risks Build
OMCL Falls 20.1% in a Month as Booking and Margin Risks Build
OMCL
Here's Why Omnicell (OMCL) is a Strong Value Stock
Here's Why Omnicell (OMCL) is a Strong Value Stock
OMCLNews tone: automated (AI) classification of the article's content, not a price prediction.
About Omnicell Inc
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Randall A. Lipps | Founder, Executive Chairman & CEO | 1957 |
| Mr. Nnamdi N. Njoku | President & COO | 1977 |
| Mr. H. Baird Radford III | Executive VP & CFO | 1970 |
| Mr. Corey J. Manley J.D. | Executive VP, Chief Legal & Administrative Officer and Corporate Secretary | 1978 |
| Mr. Brian H. Nutt | VP, Chief Accounting Officer & Corporate Controller | 1970 |
| Dr. Perry A. Genova Ph.D. | Senior VP & CTO | — |
| Mr. David Unger | Vice President of Investor Relations | — |
| Mr. Tomer Stavitsky | Senior VP & Chief Corporate Development Officer | — |
| Ms. Stella Prefach | Senior VP & Chief Marketing Officer | — |
| Mr. Dave Ford | SVP & Chief People Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 17, 2026
Technical indicators
- RSI 14
- 57.17
- MACD 12/26/9
- 0.45
- EMA 9 of MACD
- 0.14
- MACD histogram
- 0.31
- SMA 50
- $34.63
- Price above SMA 50
- EMA 50
- $35.44
- Price above EMA 50
- SMA 200
- $39.69
- Price below SMA 200
- EMA 200
- $38.10
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $45.00
- Average
- $53.33
- High
- $65.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +9.2 | +1.5 | +2.3 | |||||||||
| 2022 | -16.8 | -14.9 | -2.3 | -15.4 | -3.3 | +4.5 | -4.6 | -8.1 | -14.6 | -14.1 | -32.4 | -1.1 |
| 2023 | +7.6 | -4.6 | +2.7 | +4.8 | +19.4 | +1.0 | -13.4 | -7.8 | -21.0 | -21.3 | -6.7 | +11.4 |
| 2024 | -13.8 | -19.3 | +10.9 | -6.4 | +19.9 | -14.4 | +9.6 | +14.5 | -0.9 | +14.8 | -4.3 | -6.5 |
| 2025 | +1.5 | -12.3 | -7.3 | -11.3 | -3.2 | -2.6 | +3.6 | +9.5 | -5.1 | +12.0 | +9.4 | +25.4 |
| 2026 | +7.4 | -15.6 | -19.1 | +22.0 | +3.1 | -3.8 | -15.6 | -6.6 | -1.3 | +7.5 |
